NEWS HIGHLIGHTSMedia Articles Related to Uloric (Febuxostat)
Gout: No Help From Vitamin C
Source: Medscape Today Headlines [2013.05.16]
In patients with gout, vitamin C supplementation at 500 mg/day, either alone or with allopurinol, did not reduce uric acid levels enough to be clinically significant.
Medscape Medical News
Vitamin C Does Not Lower Uric Acid Levels In Gout Patients
Source: Gout News From Medical News Today [2013.05.16]
Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout...
Vitamin C No Help in Gout (CME/CE)
Source: MedPage Today Nephrology [2013.05.16]
(MedPage Today) -- Vitamin C supplements didn't lower uric acid levels in patients with gout when given either alone or in combination with allopurinol, an open-label pilot study showed.
UL Medical School Researchers Find Increased Death Risk In Patients Suffering From Gout And Elevated Uric Acid Levels
Source: Gout News From Medical News Today [2013.05.02]
A new study led by researchers at the Graduate Entry Medical School (GEMS), University of Limerick (UL) has found that people suffering from gout and elevated serum uric acid have significantly increased risks of death. In their study, individuals with a diagnosis of gout experienced a 42 % higher risk of death from all causes and a 58% higher risk of cardiovascular death...
Shedding Light On Gout: Repair Of Protein Pump Possible
Source: Gout News From Medical News Today [2013.04.10]
Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream. By comparing this protein pump to a related protein involved in cystic fibrosis, the researchers also identified a compound that partially repairs the pump in laboratory tests...
Published Studies Related to Uloric (Febuxostat)
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. [2011.07]
OBJECTIVE: Hyperuricemia of gout can arise due to either overproduction or underexcretion of uric acid. Not all available urate-lowering therapies are equally effective and safe for use in patients with renal disease. The objective of this post-hoc analysis was to determine the effectiveness of the xanthine oxidase inhibitor febuxostat in reducing serum urate (sUA) levels in gouty patients who were either overproducers or underexcretors... CONCLUSION: Febuxostat is a highly efficacious urate-lowering therapy in patients with gout regardless of overproduction or underexcretion status.
An allopurinol-controlled, multicenter, randomized, open-label, parallel
between-group, comparative study of febuxostat (TMX-67), a non-purine-selective
inhibitor of xanthine oxidase, in patients with hyperuricemia including those
with gout in Japan: phase 2 exploratory clinical study. [2011]
gout in Japan to compare its efficacy and safety with those of allopurinol... CONCLUSIONS: These results suggest that febuxostat is safe at doses of 40 and 60
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel
between-group, comparative study of febuxostat (TMX-67), a non-purine-selective
inhibitor of xanthine oxidase, in patients with hyperuricemia including those
with gout in Japan: phase 3 clinical study. [2011]
these drugs... CONCLUSIONS: Febuxostat at 40 mg/d demonstrated more potent hypouricemic effects
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. [2010]
INTRODUCTION: The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8.0 mg/dL in a six-month trial... CONCLUSIONS: Urate-lowering efficacy of febuxostat 80 mg exceeded that of febuxostat 40 mg and allopurinol (300/200 mg), which were comparable. In subjects with mild/moderate renal impairment, both febuxostat doses were more efficacious than allopurinol and equally safe. At the doses tested, safety of febuxostat and allopurinol was comparable. CLINICAL TRIAL REGISTRATION: NCT00430248.
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. [2009.02]
OBJECTIVES: This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout. The primary efficacy end-point was reduction to and maintenance of serum urate (sUA) levels < 6.0 mg/dl... CONCLUSIONS: Long-term treatment with febuxostat resulted in durable maintenance of sUA < 6.0 mg/dl for most subjects. There was nearly complete abolition of gout flares in patients completing the study. Baseline tophi resolved in a majority of subjects.
Clinical Trials Related to Uloric (Febuxostat)
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment [Recruiting]
The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice
daily (BID), on renal function in gout subjects with elevated serum urate levels and who
have moderate to severe renal impairment.
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease [Recruiting]
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic
syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia
induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of
uric acid with febuxostat we hypothesize that the levels of oxidative stress in adipose
tissue (obtained by fat biopsy) will decrease.
Primary aims of the study is to determine whether febuxostat therapy in overweight or obese,
diabetic patients with stage 3 CKD and high serum uric acid levels
1. decreases adipose tissue concentrations of thiobarbituric acid reactive substance
(TBARS), a marker of oxidative stress
2. increases adipose tissue expression and concentrations of adiponectin and
3. decreases urinary concentrations of transforming growth factor (TGF)- B1.
The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina [Not yet recruiting]
The purpose of this study is to assess the affect of febuxostat on coronary artery flow in
patients with coronary artery disease.
An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. [Not yet recruiting]
The purpose of this study is to show that patients with gout suffer from chronic
inflammation of their joints, observable by MRI, even in the absence of symptomatic gouty
attacks. Secondary end-points of this study will include analyzing the effects of uric
acid-lowering therapy (specifically with the FDA approved medication Febuxostat) in a
subgroup of patients, checking for the presence of inflammatory markers to see if there is
any correlation with the proposed chronic inflammation, and evaluating for other
characteristic findings of gout on MRI.
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout [Recruiting]
This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint
damage in subjects with elevated serum urate levels and gout.
Reports of Suspected Uloric (Febuxostat) Side Effects
Gout (11),
Renal Failure Acute (9),
Rash (7),
Condition Aggravated (6),
Diarrhoea (5),
Oedema Peripheral (4),
Nausea (4),
Jaundice (3),
Erythema (3),
Dizziness (3), more >>
|
